ChromaDex (CDXC) 10-Q/A 5 Dec 13 2013 Q2 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 29, 2013	Aug. 12, 2013
Document And Entity Information	'	'
Entity Registrant Name	'ChromaDex Corp.	'
Entity Central Index Key	'0001386570	'
Document Type	'10-Q	'
Document Period End Date	29-Jun-13	'
Amendment Flag	'true	'
Amendment Description	'This Quarterly Report on Form 10-Q/A of ChromaDex Corporation (the “Company”) for the quarterly period ended June 29, 2013 includes restated condensed consolidated balance sheet as of June 29, 2013, condensed consolidated statements of operations for the three and six months ended June 29, 2013, condensed consolidated statement of cash flows for the six months ended June 29, 2013 and restated notes to such condensed consolidated financial statements. This restatement is to reflect a correction in the manner in which the Company has accounted for the sale of the BluScience assets to NeutriSci International, Inc. (“NeutriSci”). The value of the equity and the senior secured convertible note that the Company received from NeutriSci as part of the purchase price were originally accounted for at their stated values which resulted in the Company recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NeutriSci equity securities and the ultimate collectability of the note received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets sold has been recovered. In addition, the Company originally accounted for its investment in NeutriSci under the cost method and the Company has now determined that the equity method should have been used. The restatement of the Company’s previously issued condensed consolidated financial statements to reflect its correction in accounting for the sale of BluScience assets to NeutriSci is referred to herein as the “Restatement.”	'
Current Fiscal Year End Date	'--12-28	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	101,307,164
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Jun. 30, 2012
Current Assets	'	'	'	'
Cash	$826,631	'	$520,000	$2,213,009
Trade receivables, less allowance for doubtful accounts and returns June 29, 2013 $17,000; December 29, 2012 $450,000	1,186,529	'	1,940,539	'
Non-trade receivable	250,000	'	'	'
Inventories	1,944,597	'	5,205,304	'
Prepaid expenses and other assets	436,455	'	261,297	'
Total current assets	4,644,212	'	7,927,140	'
Leasehold Improvements and Equipment, net	1,012,963	'	936,426	'
Other Noncurrent Assets	'	'	'	'
Deposits	41,192	'	34,773	'
Long-term investment in affiliate (Note 4)	2,157,804	'	'	'
Intangible assets, net	165,561	'	136,182	'
Total other noncurrent assets	2,364,557	'	170,955	'
Total assets	8,021,732	'	9,034,521	'
Current Liabilities	'	'	'	'
Accounts payable	2,152,023	'	3,428,233	'
Accrued expenses	711,503	'	876,158	'
Current maturities of capital lease obligations	110,382	'	77,259	'
Customer deposits and other	336,824	'	310,267	'
Deferred rent, current	51,743	'	71,042	'
Total current liabilities	3,362,475	'	4,762,959	'
Capital lease obligations, less current maturities	238,287	'	148,374	'
Deferred rent, less current	152,456	'	129,859	'
Stockholders' Equity	'	'	'	'
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding June 29, 2013 100,807,164 and December 29, 2012 92,140,062 shares	100,807	'	92,140	'
Additional paid-in capital	36,329,257	'	33,617,801	'
Accumulated deficit	-32,161,550	'	-29,716,612	'
Total stockholders' equity	4,268,514	3,841,677	3,993,329	'
Total liabilities and stockholders' equity	$8,021,732	'	$9,034,521	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 29, 2013	Dec. 29, 2012
Statement of Financial Position [Abstract]	'	'
Trade receivables, less allowance for doubtful accounts and returns	$17,000	$450,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	100,807,164	92,140,062
Common Stock, Shares, Outstanding	100,807,164	92,140,062

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012
Income Statement [Abstract]	'	'	'	'
Sales	$2,706,896	$2,670,611	$5,041,462	$4,455,617
Cost of sales	1,746,158	1,905,916	3,407,884	4,295,136
Gross profit	960,738	764,695	1,633,578	160,481
Operating expenses:	'	'	'	'
Sales and marketing	631,559	1,868,418	1,360,983	3,727,080
General and administrative	1,342,280	2,883,728	2,702,181	4,845,639
Operating expenses	1,973,839	4,752,149	4,063,164	8,572,719
Operating loss	-1,013,101	-3,987,451	-2,429,586	-8,412,238
Nonoperating income (expense):	'	'	'	'
Interest income	296	1,056	500	2,255
Interest expense	-8,061	-7,562	-15,852	-15,827
Nonoperating expenses	-7,765	-6,506	-15,352	-13,572
Net loss	($1,020,866)	($3,993,957)	($2,444,938)	($8,425,810)
Basic and Diluted net loss per common share	($0.01)	($0.04)	($0.03)	($0.10)
Basic and Diluted weighted average common shares outstanding	99,833,963	91,362,664	97,230,043	88,034,429

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 29, 2012	$92,140	$33,617,801	($29,716,612)	$3,993,329
Beginning Balance, Shares at Dec. 29, 2012	92,140,062	'	'	'
Exercise of stock options, Amount	14	6,755	'	6,769
Exercise of stock options, Shares	13,538	'	'	'
Exercise of warrants, Amount	3,414	713,585	'	716,999
Exercise of warrants,Shares	3,414,283	'	'	'
Share-based compensation, Amount	440	548,212	'	548,652
Share-based compensation, Shares	440,000	'	'	'
Net loss, as restated (Note 2)	'	'	-1,424,072	-1,424,072
Ending Balance, Amount, as restated (Note 2) at Mar. 30, 2013	96,008	34,886,353	-31,140,684	3,841,677
Ending Balance, Shares at Mar. 30, 2013	96,007,883	'	'	'
Exercise of stock options, Amount	250	124,750	'	125,000
Exercise of stock options, Shares	250,000	'	'	'
Exercise of warrants, Amount	4,389	917,360	'	921,749
Exercise of warrants,Shares	4,389,281	'	'	'
Share-based compensation, Amount	160	400,794	'	400,954
Share-based compensation, Shares	160,000	'	'	'
Net loss, as restated (Note 2)	'	'	-1,020,866	-1,020,866
Ending Balance, Amount, as restated (Note 2) at Jun. 29, 2013	$100,807	$36,329,257	($32,161,550)	$4,268,514
Ending Balance, Shares at Jun. 29, 2013	100,807,164	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 29, 2013	Jun. 30, 2012
Cash Flows From Operating Activities	'	'
Net loss	($2,444,938)	($8,425,810)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation of leasehold improvements and equipment	134,325	166,748
Amortization of intangibles	10,621	6,799
Share-based compensation expense	728,349	1,264,524
Loss from disposal of equipment	'	1,879
Changes in operating assets and liabilities:	'	'
Trade receivables	770,994	-264,536
Inventories	-206,824	-2,348,197
Prepaid expenses and other assets	-51,010	369,527
Accounts payable	-907,337	1,151,141
Accrued expenses	-150,095	-213,521
Customer deposits and other	26,557	-30,081
Deferred rent	3,298	-30,034
Net cash used in operating activities	-2,086,060	-8,351,561
Cash Flows From Investing Activities	'	'
Purchases of leasehold improvements and equipment	-39,011	-12,214
Purchase of intangible assets	-40,000	-2,000
Proceeds from sale of assets	750,000	'
Net cash provided by (used in) investing activities	670,989	-14,214
Cash Flows From Financing Activities	'	'
Proceeds from issuance of common stock, net of issuance costs	'	10,158,438
Proceeds from exercise of stock options	131,769	'
Proceeds from exercise of warrants	1,638,748	45,000
Principal payments on capital leases	-48,815	-44,806
Net cash provided by financing activities	1,721,702	10,158,632
Net increase in cash	306,631	1,792,857
Cash Beginning of Period	520,000	420,152
Cash Ending of Period	826,631	2,213,009
Supplemental Disclosures of Cash Flow Information	'	'
Cash payments for interest	15,852	15,827
Supplemental Schedule of Noncash Investing Activity	'	'
Capital lease obligation incurred for the purchase of equipment	171,851	50,786
Supplemental Schedule of Noncash Share-based Compensation	'	'
Stock awards issued for services prior to the period	14,560	'
Changes in stock and warrant awards issued for future services	206,697	'
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line	'	'
Assets transferred	3,526,677	'
Liabilities transferred	368,873	'
Carrying value of long-term investment in affiliate, net of $750,000 cash proceeds and $250,000 non-trade receivable	$2,157,804	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	6 Months Ended
	Jun. 29, 2013
Statement of Cash Flows [Abstract]	'
Cash proceeds	$750,000
Non-trade receivable	$250,000

Interim_Financial_Statements

Interim Financial Statements	6 Months Ended
	Jun. 29, 2013
Interim Financial Statements	'
Note 1. Interim Financial Statements [Text Block]	'
	The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company's financial position as of June 29, 2013 and results of operations and cash flows for the three and six months ended June 29, 2013 and June 30, 2012. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 29, 2012 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 29, 2013. Operating results for the six months ended June 29, 2013 are not necessarily indicative of the results to be achieved for the full year ending on December 28, 2013.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	The balance sheet at December 29, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	6 Months Ended
	Jun. 29, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 2. Restatement of Previously Issued Financial Statements	'
	On November 18, 2013, during the review of the interim financial statements, the Company determined that the previously issued financial statements for the three month period and the six month period ending March 30, 2013 and June 29, 2013, respectively, contained in the Company’s Quarterly Reports on Form 10-Q (“ Quarterly Reports”) for the period ended March 30, 2013 (as filed with the Securities and Exchange Commission on May 10, 2013) and June 29, 2013 (as filed with the Securities and Exchange Commission on August 13, 2013), respectively, should no longer be relied upon because of certain non-cash errors in the Quarterly Reports and that those financial statements (the “Financial Statements”) would be restated to make the necessary accounting adjustments.
	The financial statements filed for the three month period ended March 30, 2013 and the six month period ended June 29, 2013 contained a misstatement pertaining to the accounting treatment of the sale of the BluScience assets to NeutriSci International, Inc. (“NeutriSci”) (See Note 4). The value of the equity and the senior secured convertible note that the Company received from NeutriSci as part of the purchase price were originally accounted for at their stated values which resulted in the Company recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NeutriSci equity securities and the ultimate collectability of the note received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets sold has been recovered. In addition, the Company originally accounted for its investment in NeutriSci under the cost method where it has now been determined that the equity method should have been used. The Company expects all amendments and restatements to the Financial Statements affected to be non-cash in nature.
	The Company has determined that the restatements of its Financial Statements resulted from a material weakness in its internal control over financial reporting, specifically related to its process and procedures related to the accounting for sale of assets in exchange for non-cash consideration. More information regarding the Company’s controls and procedures is set forth in Part I, Item 4 of this Form 10-Q/A.
	The restatement adjustments to the previously issued financial statements for the six month period ended June 29, 2013 are as follows:
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Balance Sheet (Unaudited)
	29-Jun-13
		Previously			Restatement			As Restated
		Reported			Adjustments
	Assets
	Current Assets
	Cash	$	826,631		$	—		$	826,631
	Trade receivables		1,186,529			—			1,186,529
	Non-trade receivable		250,000			—			250,000
	Note receivable, current		1,623,508			(1,623,508	)		—
	Inventories		1,944,597			—			1,944,597
	Prepaid expenses and other assets		436,455			—			436,455
	Total current assets		6,267,720			(1,623,508	)		4,644,212
	Leasehold Improvements and Equipment, net		1,012,963			—			1,012,963
	Other Noncurrent Assets
	Deposits		41,192			—			41,192
	Note receivable, less current		779,205			(779,205	)		—
	Long-term equity investment		2,678,832			(2,678,832	)		—
	Long-term investment in affiliate		—			2,157,804			2,157,804
	Intangible assets, net		165,561			—			165,561
	Total other noncurrent assets		3,664,790			(1,300,233	)		2,364,557
	Total assets	$	10,945,473		$	(2,923,741	)	$	8,021,732
	Liabilities and Stockholders' Equity
	Current Liabilities
	Accounts payable	$	2,152,023		$	—		$	2,152,023
	Accrued expenses		711,503			—			711,503
	Current maturities of capital lease obligations		110,382			—			110,382
	Customer deposits and other		336,824			—			336,824
	Deferred rent, current		51,743			—			51,743
	Total current liabilities		3,362,475			—			3,362,475
	Capital lease obligations, less current maturities		238,287			—			238,287
	Deferred rent, less current		152,456			—			152,456
	Stockholders' Equity
	Common stock		100,807			—			100,807
	Additional paid-in capital		36,329,257			—			36,329,257
	Accumulated deficit		(29,237,809	)		(2,923,741	)		(32,161,550	)
	Total stockholders' equity		7,192,255			(2,923,741	)		4,268,514
	Total liabilities and stockholders' equity	$	10,945,473		$	(2,923,741	)	$	8,021,732
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Statement of Operations (Unaudited)
	For the Three Month Periods Ended June 29, 2013
		Previously			Restatement			As Restated
		Reported			Adjustments
	Sales	$	2,706,896		$	—		$	2,706,896
	Cost of sales		1,746,158			—			1,746,158
	Gross profit		960,738			—			960,738
	Operating expenses:
	Sales and marketing		631,559			—			631,559
	General and administrative		1,342,280			—			1,342,280
	Operating expenses		1,973,839			—			1,973,839
	Operating loss		(1,013,101	)		—			(1,013,101	)
	Nonoperating income (expense):
	Interest income		31,440			(31,144	)		296
	Interest expense		(8,061	)		—			(8,061	)
	Nonoperating income (expenses)		23,379			(31,144	)		(7,765	)
	Net loss	$	(989,722	)	$	(31,144	)	$	(1,020,866	)
	Basic and Diluted net loss per common share	$	(0.01	)	$	(0.00	)	$	(0.01	)
	Basic and Diluted weighted average common shares outstanding		99,833,963			—			99,833,963
ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Operations (Unaudited)
For the Six Month Period Ended June 29, 2013
	Previously			Restatement			As Restated
	Reported			Adjustments
Sales	$	5,041,462		$	—		$	5,041,462
Cost of sales		3,407,884			—			3,407,884
Gross profit		1,633,578			—			1,633,578
Operating expenses:
Sales and marketing		1,360,983			—			1,360,983
General and administrative		2,702,181			—			2,702,181
Gain on sale of assets		(2,891,917	)		2,891,917			—
Operating expenses		1,171,247			2,891,917			4,063,164
Operating income (loss)		462,331			(2,891,917	)		(2,429,586	)
Nonoperating income (expense):
Interest income		32,324			(31,824	)		500
Interest expense		(15,852	)		—			(15,852	)
Nonoperating income (expenses)		16,472			(31,824	)		(15,352	)
Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
Basic net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
Diluted net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
Basic weighted average common shares outstanding		97,230,043			—			97,230,043
Diluted weighted average common shares outstanding		97,486,066			(256,023	)		97,230,043
ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Cash Flows (Unaudited)
For the Six Month Period Ended June 29, 2013
	Previously			Restatement			As Restated
	Reported			Adjustments
Cash Flows From Operating Activities
Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of leasehold improvements and equipment		134,325			—			134,325
Amortization of intangibles		10,621			—			10,621
Share-based compensation expense		728,349			—			728,349
Gain on sale of assets		(2,891,917	)		2,891,917			—
Interest added to note receivable		(31,824	)		31,824			—
Changes in operating assets and liabilities:					—
Trade receivables		770,994			—			770,994
Inventories		(206,824	)		—			(206,824	)
Prepaid expenses and other assets		(51,010	)		—			(51,010	)
Accounts payable		(907,337	)		—			(907,337	)
Accrued expenses		(150,095	)		—			(150,095	)
Customer deposits and other		26,557			—			26,557
Deferred rent		3,298			—			3,298
Net cash used in operating activities		(2,086,060	)		—			(2,086,060	)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment		(39,011	)		—			(39,011	)
Purchase of intangible assets		(40,000	)		—			(40,000	)
Proceeds from sale of assets		750,000			—			750,000
Net cash provided by investing activities		670,989			—			670,989
Cash Flows From Financing Activities
Proceeds from exercise of stock options		131,769			—			131,769
Proceeds from exercise of warrants		1,638,748			—			1,638,748
Principal payments on capital leases		(48,815	)		—			(48,815	)
Net cash provided by financing activities		1,721,702			—			1,721,702
Net increase in cash		306,631			—			306,631
Cash Beginning of Period		520,000			—			520,000
Cash Ending of Period	$	826,631		$	—		$	826,631

Nature_of_Business_and_Signifi

Nature of Business and Significant Accounting Policies	6 Months Ended
	Jun. 29, 2013
Nature Of Business And Significant Accounting Policies	'
Note 3. Nature of Business and Significant Accounting Policies [Text Block]	'
	Nature of business:  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting.  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries at various terms.
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  The allowances for doubtful accounts for the periods ended June 29, 2013 and December 29, 2012 were $17,000 and $450,000, respectively.  Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the Company's BluScience retail consumer line.  The hold was placed by the retailer as an offset in the event of future returns of the Company's products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheet is recorded net of valuation allowances of $225,000 and $366,000 for the periods ended June 29, 2013 and December 29, 2012, respectively.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci.  The amounts of major classes of inventory as of June 29, 2013 and December 29, 2012 are as follows:
		29-Jun-13		29-Dec-12
	Natural product fine chemicals	$	1,656,702	$	1,614,755
	Bulk ingredients		512,895		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,169,597		5,571,304
	Less valuation allowance		225,000		366,000
		$	1,944,597	$	5,205,304
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods.   For the three- and six-month periods ended June 29, 2013 and June 30, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- and six-month periods ended June 29, 2013 and June 30, 2012.
		Three Months Ended				Six Months Ended
			29-Jun-13	June 30,			29-Jun-13	June 30,
				2012				2012
	Basic weighted average common shares outstanding		99,833,963		91,362,664		97,230,043		88,034,429
	Warrants and options in the money, net		319,587		5,693,386		256,023		6,101,236
	Weighted average common shares outstanding assuming dilution		100,153,550		97,056,050		97,486,066		94,135,665
	Total warrants and options that were not “in the money” at June 29, 2013 and June 30, 2012 were 11,595,211 and 15,071,066, respectively.
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method.  The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee.  Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method.  The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary.  Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Sale_of_Product_Line_and_Inves

Sale of Product Line and Investment in Affiliate	6 Months Ended
	Jun. 29, 2013
Receivables [Abstract]	'
Note 4. Sale of Product Line and Investment in Affiliate	'
	On March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci and consummated the sale of BluScience consumer product line to NeutriSci.  The Company is using the cost recovery method to account for the sale transaction, which is estimated at approximately $3,157,804. The consideration received consists of following: (a) a $250,000 cash payment, which NeutriSci paid as a deposit in February 2013; (b) an additional $250,000 cash payment, which was paid at the closing of the sale;  (c) an additional cash payment of $500,000 due no later than 60 days after the closing of the sale, which $250,000 was paid as of June 29, 2013 and an additional $200,000 was paid on July 12, 2013; (d) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock as described below) payable in quarterly installments of $416,667 beginning August 15, 2013; and (e) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at a deemed price for each Class A common share of $1.00 per share.  The transaction documents contain certain equity blockers that preclude the Company's ownership in NeutriSci in excess of 9.99% and 19% without obtaining a waiver from NeutriSci.  The Company will continue to generate revenue through a royalty on 6% of future net sales of BluScience products as well as a supply agreement with NeutriSci for the Company's patented pTeroPure pterostilbene. As of June 29, 2013, the Company did not have any sales to NeutriSci under this supply agreement for pTeroPure pterostilbene.
	The Company has applied the equity method of accounting for the 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci and the carrying value, which includes the senior convertible secured note, is reflected as long-term investment in affiliate in the Company’s consolidated balance sheet as of June 29, 2013.  The initial carrying value of this investment recognized, as restated, as of March 28, 2013 was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received.  Although, (i) other contemporaneous third party investments in NeutriSci’s Class “A” common shares were $1.00 per share and (ii) the face value of the senior convertible secured note was $2,500,000, management believed that $2,157,804 was the appropriate aggregate carrying value for the investment in affiliate, considering the fact that NeutriSci is a start-up company and has historically recorded significant operating losses.  The Company is unable to determine NeutriSci’s likelihood of repaying the note, and because of this significant uncertainty, the amount of collectability of the senior convertible secured note is not ascertainable.  There is a significant uncertainty in the realization of value of the Series I Preferred Shares as well.  Consequently, management deemed it appropriate to consider that both the 669,708 shares of Series I Preferred Shares and the senior convertible secured note as one long term investment in affiliate.  Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered.  Prospective collection of payments under the note will be charged against the carrying value of the long-term investment in affiliate.  The below table illustrates how the carrying value was determined.
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
	The Company has elected to record equity method adjustments in gains (losses) on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner. At such, for the Company’s three- and six-month periods ended June 29, 2013, the Company did not record equity method adjustments corresponding to the three-month lag after closing the investment on March 28, 2013. When the financial information is available at a later time, the Company will use NeutriSci’s financial statements for the period beginning on April 1, 2013. This will not cover the three-day period from March 28, 2013 to March 30, 2013, which is also a portion of the Company’s investment period since the Company’s investment started from March 28, 2013. However, the Company has determined that the amount of any impact to the Company for the three day period not covered was immaterial as NeutriSci did not have any significant transactions.
	As of June 29, 2013, $250,000 cash payment remained unpaid and this amount is reflected as non-trade receivable in the Company's consolidated balance sheet as of June 29, 2013. Of this unpaid amount, a partial payment of $200,000 was received on July 12, 2013.
	The senior secured convertible note is secured by the Security Agreement, dated March 28, 2013 entered into between the Company and NeutriSci whereby NeutriSci granted the Company a security interest in substantially all of NeutriSci’s assets, including inventory, to secure its obligations pursuant to the note.   In the event of default, the note can also be convertible into Series I Preferred Shares of NeutriSci at the option of ChromaDex.  Each Series I Preferred Share can be convertible into 4 Class A common shares of NeutriSci.  The conversion price will be (a) $4.00 per Series I Preferred Share prior to a Public Offering (as defined in the note); or (b) the closing price of Series I Preferred Share or four times the closing price of Class A common share on a stock exchange immediately prior to the conversion date.
	Under the asset purchase and sale agreement entered into as of March 28, 2013 with the Company, NeutriSci is obligated to file an initial public offering prospectus with a securities commission in Canada no later than September 24, 2013 (or 180 days from the closing date of March 28, 2013) and to concurrently seek approval of the listing of its common shares on the TSX Venture Exchange or similar stock exchange in Canada.
	As of June 29, 2013, the Company has determined that there is no other-than-temporary impairment, as the Company is not aware of any other-than-temporary impairment triggering events or indicators.  The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	6 Months Ended
	Jun. 29, 2013
Leasehold Improvements And Equipment	'
Note 5. Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		29-Jun-13		29-Dec-12
	Laboratory equipment	$	2,563,238	$	2,439,688
	Leasehold improvements		403,971		403,971
	Computer equipment		370,692		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		186,439		106,080
			3,550,530		3,339,668
	Less accumulated depreciation		2,537,567		2,403,242
		$	1,012,963	$	936,426

Employee_ShareBased_Compensati

Employee Share-Based Compensation	6 Months Ended
	Jun. 29, 2013
Employee Share-Based Compensation	'
Note 6. Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of the Company’s compensation committee (the “Compensation Committee”), and with the approval of the Company’s board of directors (the “Board of Directors”), the Company may grant options to purchase the Company’s common stock to certain individuals from time to time. Management and the Compensation Committee determine the terms of awards which include the exercise price, vesting conditions and expiration dates at the time of grant. Expiration dates for stock options are not to exceed 10 years from their date of issuance. The Company, under its Second Amended and Restated 2007 Equity Incentive Plan, is authorized to issue stock options that total no more than 20% of the shares of common stock issued and outstanding, as determined on a fully diluted basis.  Beginning in 2007, stock options were no longer issuable under the Company’s 2000 Non-Qualified Incentive Stock Plan.  The remaining amount available for issuance under the Second Amended and Restated 2007 Equity Incentive Plan totaled 6,164,537 at June 29, 2013. The stock option awards generally vest ratably over a four-year period following grant date after a passage of time.  However, some stock option awards are performance based and vest based on the achievement of certain criteria established by the Compensation Committee, subject to approval by the Board of Directors.
	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes based option valuation model.  The table below outlines the weighted average assumptions for options granted to employees during the six months ended June 29, 2013
	Six Months Ended June 29, 2013
	Volatility		32.68	%
	Expected dividends		0	%
	Expected term	6.1 years
	Risk-free rate		1.18	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries, as the historical volatility of the Company’s common stock does not cover the period equal to the expected life of the options.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The expected term of the options represents the estimated period of time until exercise and is based on historical experience of awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior.  The estimation process for the fair value of performance based stock options was the same as for service period based options.
	1) Service Period Based Stock Options
	The majority of options granted by the Company are comprised of service based options granted to employees.  These options vest ratably over a defined period following grant date after a passage of a service period.
	The following table summarizes service period based stock options activity at June 29, 2013 and changes during the six months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		310,000			0.68
	Options Exercised		(13,538	)		0.5
	Options Expired		(75,000	)		0.5
	Options Forfeited		(149,168	)		1.24
	Outstanding at June 29, 2013		12,274,852		$	1.08		7.86	$	375,554
	Exercisable at June 29, 2013		6,035,944		$	1.24		6.48	$	202,092
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.78 on the last day of business for the period ended June 29, 2013. The weighted average fair value of options granted during the six months ended June 29, 2013 and June 30, 2012 was $0.24 and $0.30 respectively. The aggregate intrinsic value for options exercised during the six months ended June 29, 2013 was $2,437. There were no options exercised during the three months ended June 29, 2013 and the three and six months ended June 30, 2012.
	2) Performance Based Stock Options
	The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee.  If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.
	The following table summarizes performance based stock options activity at June 29, 2013 and changes during the six months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at June 29, 2013		300,000		$	0.95		9	$	30,200
	Exercisable at June 29, 2013		52,084		$	1.59		7.85	$	-
	The aggregate intrinsic value in the table above are before income taxes, based on the Company’s closing stock price of $0.78 on the last day of business for the period ended June 29, 2013.  The weighted average fair value of options granted during the six months ended June 29, 2013 was $0.22.  The Company did not grant any performance based stock options during the three months ended June 29, 2013 and the three and six months ended June 30, 2012.
	As of June 29, 2013, there was $1,945,157 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options. That cost is expected to be recognized over a weighted average period of 2.44 years as of June 29, 2013.  The realized tax benefit from stock options for the six months ended June 29, 2013, and June 30, 2012 was $0, based on the Company’s full valuation allowance against its deferred tax assets.
	Restricted Stock
	Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.
	The following table summarizes activity of restricted stock awards granted to employees at June 29, 2013 and changes during the six months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at June 29, 2013		500,000		$	0.69
	Expected to Vest as of June 29, 2013		500,000		$	0.69
	As of June 29, 2013, the Company did not have any unrecognized compensation expense related to restricted stock awards to employees.
	For employee share-based compensation, the Company recognized share-based compensation expense of $286,417 and $572,951 in general and administrative expenses in the statement of operations for the three and six months ended June 29, 2013, respectively.  The Company recognized $939,960 and $643,825 in share-based compensation expense for the three and six months ended June 30, 2012, respectively.

NonEmployee_ShareBased_Compens

Non-Employee Share-Based Compensation	6 Months Ended
	Jun. 29, 2013
Non-Employee Share-Based Compensation	'
Note 7. Non-Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of management, working with the Compensation Committee, and with approval of the Board of Directors, the Company may grant options to purchase the Company’s common stock to certain individuals from time to time who are not employees of the Company.  These options are granted under the Second Amended and Restated 2007 Equity Incentive Plan of the Company and are granted on the same terms as those being issued to employees.  Stock options granted to non-employees are accounted for using the fair value approach.  The fair value of non-employee option grants are estimated using the Black-Scholes option-pricing model and are re-measured over the vesting term until earned.  The estimated fair value is expensed over the applicable service period.
	The following table summarizes activity of stock options granted to non-employees at June 29, 2013 and changes during the six months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at June 29, 2013		847,300		$	1.44		6.23	$	11,670
	Exercisable at June 29, 2013		847,300		$	1.44		6.23	$	11,670
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.78 on the last day of business for the period ended June 29, 2013.  The aggregate intrinsic value for options exercised during the three and six months ended June 29, 2013 were $35,000 for both periods as there were no options exercised during the three months ended March 30, 2013.  There were no options exercised during the three and six months ended June 30, 2012.
	As of June 29, 2013, the Company did not have any unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for non-employee stock options.
	Stock Awards
	From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided.  If the fair value of services received is more reliably measurable than the fair value of the stock awarded, the fair value of the services received is used to measure the award.  In contrast, if the fair value of the stock issued is more reliably measurable, than the fair value of services received, the award is measured based on the fair value of the stock awarded.  Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.  The measured fair value of the award is amortized over the period the service is provided.
	During the three and six months ended June 29, 2013, the Company awarded an aggregate of 160,000 and 600,000 shares of the Company’s common stock to non-employees, respectively.  The fair values of the awards were based on the trading price of the Company’s stock on the date of issuance.  The expense the Company recognized for stock awards was $88,071 and $150,249 for the three and six months ended June 29, 2013, respectively.  As of June 29, 2013, there was $230,276 of total unrecognized compensation expense related to stock awarded to the non-employees.  During the three and six months ended June 30, 2012, the Company awarded an aggregate of 265,000 and 454,557 shares, respectively, and recognized a total expense of $181,260 and $308,176, respectively.
	Warrant Awards
	During the three and six months ended June 29, 2013, the Company recognized an expense of $1,334 and $4,094, respectively, for the warrants that were previously awarded during the year ended December 29, 2012.  The Company did not award any new warrants during the three and six months ended June 29, 2013.  As of June 29, 2013, the Company did not have any unrecognized compensation expense related to warrants awarded to the non-employee.
	For non-employee share-based compensation, the Company recognized share-based compensation expense of $90,342 and $155,398 in general and administrative expenses in the statement of operations for the three and six months ended June 29, 2013, respectively. The Company recognized $258,578 and $620,700 in share-based compensation expense for the three and six months ended June 30, 2012, respectively.

Warrants

Warrants	6 Months Ended
	Jun. 29, 2013
Warrants	'
Note 8. Warrants	'
	During the three and six months ended June 29, 2013, 4,389,281 and 7,803,564 warrants with an exercise price of $0.21 per share were exercised, respectively, and the Company received proceeds of $921,749 and $1,638,748 from exercise of these warrants, respectively.  These warrants were issued during the year ended January 1, 2011 pursuant to a subscription agreement entered into by the holders of such warrants and the Company on April 22, 2010.
	In addition, during the three and six months ended June 29, 2013, 533,067 and 1,314,303 warrants issued during the year 2008 with an exercise price of $3.00 per share expired, respectively.
	At June 29, 2013, the following warrants were outstanding and exercisable:
	Warrants granted	Weighted Average		Number Outstanding		Weighted Average
	in connection with :	Exercise Prices		And Exercisable		Remaining Contractual Life
				At June 29, 2013
	2008 Private placement equity offering	$	3		404,047	0.8 month
	2012 Placement agent commission	$	0.85		285,000	13.1 months
	2012 Non-employee award	$	0.75		250,000	13.3 months
		$	1.75		939,047	7.9 months

Business_Segmentation

Business Segmentation	6 Months Ended
	Jun. 29, 2013
Business Segmentation	'
Note 9. Business Segmentation	'
	Since the year ended December 29, 2012, the Company began segregating its financial results for Spherix Consulting, Inc. (“Spherix”), which the Company acquired on December 3, 2012.  Spherix provides scientific and regulatory consulting.  The Company has following three reportable segments.
		·	Core standards, contract services and ingredients segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, and reference materials, related contract services, and proprietary ingredients.
		·	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
		·	Retail dietary supplement products segment which consist of the supply of the BluScience line of dietary supplement products containing the Company's proprietary ingredients to various retail distribution channels.  On March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci and consummated the sale of BluScience consumer product line to NeutriSci.
	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
	Three months ended		Core Standards,							Retail
	29-Jun-13		Contract Services and			Scientific and				Dietary Supplement
						Regulatory
			Ingredients segment			Consulting segment				Products segment				Other			Total
	Net sales		$	2,504,372		$	202,524			$	—			$	—		$	2,706,896
	Cost of sales			1,614,413			131,745				—				—			1,746,158
	Gross profit			889,959			70,779				—				—			960,738
	Operating expenses:
	Sales and marketing			630,447			1,112				—				—			631,559
	General and administrative			—			—				—				1,342,280			1,342,280
	Operating expenses			630,447			1,112				—				1,342,280			1,973,839
	Operating income (loss)		$	259,512		$	69,667			$	—			$	(1,342,280	)	$	(1,013,101	)
	Three months ended		Core Standards,							Retail
	30-Jun-12		Contract Services and			Scientific and				Dietary Supplement
						Regulatory
			Ingredients segment			Consulting segment				Products segment				Other			Total
	Net sales		$	2,150,585		$	—			$	520,026			$	—		$	2,670,611
	Cost of sales			1,528,203			—				377,713				—			1,905,916
	Gross profit			622,382			—				142,313				—			764,695
	Operating expenses:
	Sales and marketing			536,572			—				1,331,846				—			1,868,418
	General and administrative			—			—				—				2,883,728			2,883,728
	Operating expenses			536,572			—				1,331,846				2,883,728			4,752,146
	Operating income (loss)		$	85,810		$	—			$	(1,189,533	)		$	(2,883,728	)	$	(3,987,451	)
	Six months ended		Core Standards,							Retail Dietary Supplement
	29-Jun-13
			Contract Services and			Scientific and				Products segment							Total
						Regulatory
			Ingredients segment			Consulting segment				(Restated,				Other			(Restated,
										Note 2)							Note 2)
	Net sales		$	4,655,885		$	445,862			$	(60,285	)		$	—		$	5,041,462
	Cost of sales			3,128,396			278,533				955				—			3,407,884
	Gross profit (loss)			1,527,489			167,329				(61,240	)			—			1,633,578
	Operating expenses:
	Sales and marketing			1,227,224			2,600				131,159				—			1,360,983
	General and administrative			—			—				—				2,702,181			2,702,181
	Operating expenses			1,227,224			2,600				131,159				2,702,181			4,063,164
	Operating income (loss)		$	300,265		$	164,729			$	(192,399	)		$	(2,702,181	)	$	(2,429,586	)
	Six months ended		Core Standards,							Retail
	30-Jun-12		Contract Services and			Scientific and				Dietary Supplement
						Regulatory
			Ingredients segment			Consulting segment				Products segment				Other			Total
	Net sales		$	4,005,333		$	—			$	450,284			$	—		$	4,455,617
	Cost of sales			2,874,825			—				1,420,311				—			4,295,136
	Gross profit (loss)			1,130,508			—				(970,027	)			—			160,481
	Operating expenses:
	Sales and marketing			1,011,516			—				2,715,564				—			3,727,080
	General and administrative			—			—				—				4,845,639			4,845,639
	Operating expenses			1,011,516			—				2,715,564				4,845,639			8,572,719
	Operating income (loss)		$	118,992		$	—			$	(3,685,591	)		$	(4,845,639	)	$	(8,412,238	)
	At June 29, 2013		Core Standards,			Retail
			Contract Services and		Scientific and	Dietary Supplement		Other				Total
					Regulatory
			Ingredients segment		Consulting segment	Products segment		(Restated,				(Restated,
								Note 2)				Note 2)
	Total assets		$3,924,625		$95,584	$-		$	4,001,523			$	8,021,732
	At December 29, 2012		Core Standards,			Retail
			Contract Services and		Scientific and	Dietary Supplement
Regulatory
		Ingredients segment		Consulting segment	Products segment		Other				Total
Total assets		$3,542,355		$72,573	$4,331,866		$	1,087,727			$	9,034,521

Managements_Plans_for_Continui

Managements Plans for Continuing Operations	6 Months Ended
	Jun. 29, 2013
Managements Plans For Continuing Operations	'
Note 10. Managements Plans for Continuing Operations	'
	The Company has incurred a net loss of $2,444,938 for the six-month period ended June 29, 2013.  and an operating loss of $2,429,586 for the six-month period ended June 29, 2013.  One of the factors that contributed to this loss is share-based compensation expense.  The Company’s share-based compensation expense totaled $728,349 for the six months ended June 29, 2013.  In addition to the stock options granted to employees, the Company has been awarding shares of its common stock to non-employees as compensation of the services provided.  Another factor that contributed to the loss is the investment in additional personnel and marketing expenses to implement its business plan to expand the line of proprietary ingredients.  This has resulted in higher selling, marketing and patent related expenses compared to prior years.  Management has also implemented additional strategic operational structure changes, which it believes, will allow the Company to achieve profitability with future growth without incurring significant additional overhead costs.  Management’s anticipation of future growth is largely related to the demand of the line of proprietary ingredients offered by the Company.  The Company also incurred an operating loss of $192,399 from BluScience operations, without the gain on sale of BluScience consumer production line.  Increase in trade accounts receivable allowance for possible future returns was the main reason for the loss from BluScience operations as the increase in allowance was treated as a reduction of revenue.
	By curtailing certain expenditures, management believes it will be able to support operations of the Company with its current cash and cash from operations through December, 2013.  In addition, on July 12, 2013, the Company received a partial payment of $200,000 from NeutriSci from the sale of BluScience consumer product line and may have prospective collections up to $883,334 from NeutriSci prior to December, 2013.
	If the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all.  If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations.  The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 29, 2013
Income Taxes	'
Note 11. Income Taxes	'
	At June 29, 2013 and December 29, 2012, the Company maintained a full valuation allowance against the entire net deferred income tax balance after considering relevant factors, including recent operating results, the likelihood of the utilization of net operating loss tax carry forwards, and the ability to generate future taxable income.  The Company expects to maintain a full valuation allowance on its entire net deferred tax assets in 2013, resulting in an effective tax rate of zero for the six months ended June 29, 2013.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 29, 2013
Subsequent Events [Abstract]	'
Note 12. Subsequent Events	'
	On July 9, 2013, Company entered in a three year supply agreement with Thorne Reseach, Inc. (“Thorne”) pursuant to which Thorne will purchase and market the Company’s patented nicotinamide riboside which is branded as NIAGEN™.  Under the terms of the agreement, Thorne has received marketing rights for NIAGEN™  for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the United States and Canada, provided that Thorne purchases a minimum of $3.5 million of NIAGEN™  product over the next three years.
	On August 1, 2013, the Company entered in License Agreement (the “Agreement”) with Green Molecular S.L., Inc. (“Green Molecular”), a Spanish corporation, pursuant to which Green Molecular granted the Company an exclusive, worldwide right and license (the “License Rights”) to use and practice certain patent rights and to make, have made, use and sell certain products, including the compound pterostilbene, as it is used in dietary supplement products.  In consideration of the License Rights, the Company has agreed to pay to Green Molecular earned royalties on net sales of all licensed products (including sales by sublicensees and affiliates), as well as a percentage of attributed income from sublicensing agreements. ChromaDex is subject to minimum annual maintenance or royalty payments to Green Molecular during the term of the Agreement.  The Company has agreed upon a plan to develop, commercialize and market licensed products under that Agreement and will make certain payments to Green Molecular in connection with the achievement of certain milestone events relating to product development and regulatory approvals in accordance with the terms of the Agreement.

Nature_of_Business_and_Signifi1

Nature of Business and Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 29, 2013
Nature Of Business And Significant Accounting Policies Policy	'
Nature of business	'
	Nature of business:  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting.  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries at various terms.
Basis of presentation	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
Trade accounts receivable	'
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  The allowances for doubtful accounts for the periods ended June 29, 2013 and December 29, 2012 were $17,000 and $450,000, respectively.  Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the Company's BluScience retail consumer line.  The hold was placed by the retailer as an offset in the event of future returns of the Company's products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
Inventories	'
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheet is recorded net of valuation allowances of $225,000 and $366,000 for the periods ended June 29, 2013 and December 29, 2012, respectively.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci.  The amounts of major classes of inventory as of June 29, 2013 and December 29, 2012 are as follows:
		29-Jun-13		29-Dec-12
	Natural product fine chemicals	$	1,656,702	$	1,614,755
	Bulk ingredients		512,895		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,169,597		5,571,304
	Less valuation allowance		225,000		366,000
		$	1,944,597	$	5,205,304
Earnings per share	'
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods.   For the three- and six-month periods ended June 29, 2013 and June 30, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- and six-month periods ended June 29, 2013 and June 30, 2012.
		Three Months Ended				Six Months Ended
			29-Jun-13	June 30,			29-Jun-13	June 30,
				2012				2012
	Basic weighted average common shares outstanding		99,833,963		91,362,664		97,230,043		88,034,429
	Warrants and options in the money, net		319,587		5,693,386		256,023		6,101,236
	Weighted average common shares outstanding assuming dilution		100,153,550		97,056,050		97,486,066		94,135,665
	Total warrants and options that were not “in the money” at June 29, 2013 and June 30, 2012 were 11,595,211 and 15,071,066, respectively.
Long-term investment in affiliate	'
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method.  The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee.  Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method.  The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary.  Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	6 Months Ended
	Jun. 29, 2013
Restatement Of Previously Issued Financial Statements Tables	'
Restatement	'
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Balance Sheet (Unaudited)
	29-Jun-13
		Previously			Restatement			As Restated
		Reported			Adjustments
	Assets
	Current Assets
	Cash	$	826,631		$	—		$	826,631
	Trade receivables		1,186,529			—			1,186,529
	Non-trade receivable		250,000			—			250,000
	Note receivable, current		1,623,508			(1,623,508	)		—
	Inventories		1,944,597			—			1,944,597
	Prepaid expenses and other assets		436,455			—			436,455
	Total current assets		6,267,720			(1,623,508	)		4,644,212
	Leasehold Improvements and Equipment, net		1,012,963			—			1,012,963
	Other Noncurrent Assets
	Deposits		41,192			—			41,192
	Note receivable, less current		779,205			(779,205	)		—
	Long-term equity investment		2,678,832			(2,678,832	)		—
	Long-term investment in affiliate		—			2,157,804			2,157,804
	Intangible assets, net		165,561			—			165,561
	Total other noncurrent assets		3,664,790			(1,300,233	)		2,364,557
	Total assets	$	10,945,473		$	(2,923,741	)	$	8,021,732
	Liabilities and Stockholders' Equity
	Current Liabilities
	Accounts payable	$	2,152,023		$	—		$	2,152,023
	Accrued expenses		711,503			—			711,503
	Current maturities of capital lease obligations		110,382			—			110,382
	Customer deposits and other		336,824			—			336,824
	Deferred rent, current		51,743			—			51,743
	Total current liabilities		3,362,475			—			3,362,475
	Capital lease obligations, less current maturities		238,287			—			238,287
	Deferred rent, less current		152,456			—			152,456
	Stockholders' Equity
	Common stock		100,807			—			100,807
	Additional paid-in capital		36,329,257			—			36,329,257
	Accumulated deficit		(29,237,809	)		(2,923,741	)		(32,161,550	)
	Total stockholders' equity		7,192,255			(2,923,741	)		4,268,514
	Total liabilities and stockholders' equity	$	10,945,473		$	(2,923,741	)	$	8,021,732
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Statement of Operations (Unaudited)
	For the Three Month Periods Ended June 29, 2013
		Previously			Restatement			As Restated
		Reported			Adjustments
	Sales	$	2,706,896		$	—		$	2,706,896
	Cost of sales		1,746,158			—			1,746,158
	Gross profit		960,738			—			960,738
	Operating expenses:
	Sales and marketing		631,559			—			631,559
	General and administrative		1,342,280			—			1,342,280
	Operating expenses		1,973,839			—			1,973,839
	Operating loss		(1,013,101	)		—			(1,013,101	)
	Nonoperating income (expense):
	Interest income		31,440			(31,144	)		296
	Interest expense		(8,061	)		—			(8,061	)
	Nonoperating income (expenses)		23,379			(31,144	)		(7,765	)
	Net loss	$	(989,722	)	$	(31,144	)	$	(1,020,866	)
	Basic and Diluted net loss per common share	$	(0.01	)	$	(0.00	)	$	(0.01	)
	Basic and Diluted weighted average common shares outstanding		99,833,963			—			99,833,963
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Statement of Operations (Unaudited)
	For the Six Month Period Ended June 29, 2013
		Previously			Restatement			As Restated
Reported			Adjustments
Sales	$	5,041,462		$	—		$	5,041,462
Cost of sales		3,407,884			—			3,407,884
Gross profit		1,633,578			—			1,633,578
Operating expenses:
Sales and marketing		1,360,983			—			1,360,983
General and administrative		2,702,181			—			2,702,181
Gain on sale of assets		(2,891,917	)		2,891,917			—
Operating expenses		1,171,247			2,891,917			4,063,164
Operating income (loss)		462,331			(2,891,917	)		(2,429,586	)
Nonoperating income (expense):
Interest income		32,324			(31,824	)		500
Interest expense		(15,852	)		—			(15,852	)
Nonoperating income (expenses)		16,472			(31,824	)		(15,352	)
Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
Basic net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
Diluted net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
Basic weighted average common shares outstanding		97,230,043			—			97,230,043
Diluted weighted average common shares outstanding		97,486,066			(256,023	)		97,230,043
ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Cash Flows (Unaudited)
For the Six Month Period Ended June 29, 2013
	Previously			Restatement			As Restated
	Reported			Adjustments
Cash Flows From Operating Activities
Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of leasehold improvements and equipment		134,325			—			134,325
Amortization of intangibles		10,621			—			10,621
Share-based compensation expense		728,349			—			728,349
Gain on sale of assets		(2,891,917	)		2,891,917			—
Interest added to note receivable		(31,824	)		31,824			—
Changes in operating assets and liabilities:					—
Trade receivables		770,994			—			770,994
Inventories		(206,824	)		—			(206,824	)
Prepaid expenses and other assets		(51,010	)		—			(51,010	)
Accounts payable		(907,337	)		—			(907,337	)
Accrued expenses		(150,095	)		—			(150,095	)
Customer deposits and other		26,557			—			26,557
Deferred rent		3,298			—			3,298
Net cash used in operating activities		(2,086,060	)		—			(2,086,060	)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment		(39,011	)		—			(39,011	)
Purchase of intangible assets		(40,000	)		—			(40,000	)
Proceeds from sale of assets		750,000			—			750,000
Net cash provided by investing activities		670,989			—			670,989
Cash Flows From Financing Activities
Proceeds from exercise of stock options		131,769			—			131,769
Proceeds from exercise of warrants		1,638,748			—			1,638,748
Principal payments on capital leases		(48,815	)		—			(48,815	)
Net cash provided by financing activities		1,721,702			—			1,721,702
Net increase in cash		306,631			—			306,631
Cash Beginning of Period		520,000			—			520,000
Cash Ending of Period	$	826,631		$	—		$	826,631

Nature_of_Business_and_Signifi2

Nature of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 29, 2013
Nature Of Business And Significant Accounting Policies Tables	'
Inventories	'
		29-Jun-13		29-Dec-12
	Natural product fine chemicals	$	1,656,702	$	1,614,755
	Bulk ingredients		512,895		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,169,597		5,571,304
	Less valuation allowance		225,000		366,000
		$	1,944,597	$	5,205,304
Earnings per share	'
		Three Months Ended				Six Months Ended
			29-Jun-13	June 30,			29-Jun-13	June 30,
				2012				2012
	Basic weighted average common shares outstanding		99,833,963		91,362,664		97,230,043		88,034,429
	Warrants and options in the money, net		319,587		5,693,386		256,023		6,101,236
	Weighted average common shares outstanding assuming dilution		100,153,550		97,056,050		97,486,066		94,135,665

Sale_of_Product_Line_and_Inves1

Sale of Product Line and Investment in Affiliate (Tables)	6 Months Ended
	Jun. 29, 2013
Sale Of Product Line And Investment In Affiliate Tables	'
Determination of carrying value	'
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	6 Months Ended
	Jun. 29, 2013
Leasehold Improvements And Equipment	'
Leasehold Improvements and Equipment	'
		29-Jun-13		29-Dec-12
	Laboratory equipment	$	2,563,238	$	2,439,688
	Leasehold improvements		403,971		403,971
	Computer equipment		370,692		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		186,439		106,080
			3,550,530		3,339,668
	Less accumulated depreciation		2,537,567		2,403,242
		$	1,012,963	$	936,426

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	6 Months Ended
	Jun. 29, 2013
Employee Share-Based Compensation Tables	'
Weighted average assumptions of stock options granted	'
	Six Months Ended June 29, 2013
	Volatility		32.68	%
	Expected dividends		0	%
	Expected term	6.1 years
	Risk-free rate		1.18	%
Service Period Based Stock Options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		310,000			0.68
	Options Exercised		(13,538	)		0.5
	Options Expired		(75,000	)		0.5
	Options Forfeited		(149,168	)		1.24
	Outstanding at June 29, 2013		12,274,852		$	1.08		7.86	$	375,554
	Exercisable at June 29, 2013		6,035,944		$	1.24		6.48	$	202,092
Performance Based Stock Options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at June 29, 2013		300,000		$	0.95		9	$	30,200
	Exercisable at June 29, 2013		52,084		$	1.59		7.85	$	-
Restricted stock awards granted to employees	'
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at June 29, 2013		500,000		$	0.69
	Expected to Vest as of June 29, 2013		500,000		$	0.69

NonEmployee_ShareBased_Compens1

Non-Employee Share-Based Compensation (Tables)	6 Months Ended
	Jun. 29, 2013
Non-Employee Share-Based Compensation Tables	'
Non-Employee stock options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at June 29, 2013		847,300		$	1.44		6.23	$	11,670
	Exercisable at June 29, 2013		847,300		$	1.44		6.23	$	11,670

Warrants_Tables

Warrants (Tables)	6 Months Ended
	Jun. 29, 2013
Warrants Tables	'
Warrants	'
	Warrants granted	Weighted Average		Number Outstanding		Weighted Average
	in connection with :	Exercise Prices		And Exercisable		Remaining Contractual Life
				At June 29, 2013
	2008 Private placement equity offering	$	3		404,047	0.8 month
	2012 Placement agent commission	$	0.85		285,000	13.1 months
	2012 Non-employee award	$	0.75		250,000	13.3 months
		$	1.75		939,047	7.9 months

Business_Segmentation_Tables

Business Segmentation (Tables)	6 Months Ended
	Jun. 29, 2013
Business Segmentation Tables	'
Business Segmentation	'
	Three months ended	Core Standards,								Retail
	29-Jun-13	Contract Services and				Scientific and				Dietary Supplement
						Regulatory
		Ingredients segment				Consulting segment				Products segment				Other			Total
	Net sales	$	2,504,372			$	202,524			$	—			$	—		$	2,706,896
	Cost of sales		1,614,413				131,745				—				—			1,746,158
	Gross profit		889,959				70,779				—				—			960,738
	Operating expenses:
	Sales and marketing		630,447				1,112				—				—			631,559
	General and administrative		—				—				—				1,342,280			1,342,280
	Operating expenses		630,447				1,112				—				1,342,280			1,973,839
	Operating income (loss)	$	259,512			$	69,667			$	—			$	(1,342,280	)	$	(1,013,101	)
	Three months ended	Core Standards,								Retail
	30-Jun-12	Contract Services and				Scientific and				Dietary Supplement
						Regulatory
		Ingredients segment				Consulting segment				Products segment				Other			Total
	Net sales	$	2,150,585			$	—			$	520,026			$	—		$	2,670,611
	Cost of sales		1,528,203				—				377,713				—			1,905,916
	Gross profit		622,382				—				142,313				—			764,695
	Operating expenses:
	Sales and marketing		536,572				—				1,331,846				—			1,868,418
	General and administrative		—				—				—				2,883,728			2,883,728
	Operating expenses		536,572				—				1,331,846				2,883,728			4,752,146
	Operating income (loss)	$	85,810			$	—			$	(1,189,533	)		$	(2,883,728	)	$	(3,987,451	)
	Six months ended	Core Standards,								Retail Dietary Supplement
	29-Jun-13
		Contract Services and				Scientific and				Products segment							Total
						Regulatory
		Ingredients segment				Consulting segment				(Restated,				Other			(Restated,
										Note 2)							Note 2)
	Net sales	$	4,655,885			$	445,862			$	(60,285	)		$	—		$	5,041,462
	Cost of sales		3,128,396				278,533				955				—			3,407,884
	Gross profit (loss)		1,527,489				167,329				(61,240	)			—			1,633,578
	Operating expenses:
	Sales and marketing		1,227,224				2,600				131,159				—			1,360,983
	General and administrative		—				—				—				2,702,181			2,702,181
	Operating expenses		1,227,224				2,600				131,159				2,702,181			4,063,164
	Operating income (loss)	$	300,265			$	164,729			$	(192,399	)		$	(2,702,181	)	$	(2,429,586	)
	Six months ended	Core Standards,								Retail
	30-Jun-12	Contract Services and				Scientific and				Dietary Supplement
						Regulatory
		Ingredients segment				Consulting segment				Products segment				Other			Total
	Net sales	$	4,005,333			$	—			$	450,284			$	—		$	4,455,617
	Cost of sales		2,874,825				—				1,420,311				—			4,295,136
	Gross profit (loss)		1,130,508				—				(970,027	)			—			160,481
	Operating expenses:
	Sales and marketing		1,011,516				—				2,715,564				—			3,727,080
	General and administrative		—				—				—				4,845,639			4,845,639
	Operating expenses		1,011,516				—				2,715,564				4,845,639			8,572,719
	Operating income (loss)	$	118,992			$	—			$	(3,685,591	)		$	(4,845,639	)	$	(8,412,238	)
	At June 29, 2013	Core Standards,				Retail
		Contract Services and		Scientific and		Dietary Supplement		Other				Total
				Regulatory
		Ingredients segment		Consulting segment		Products segment		(Restated,				(Restated,
								Note 2)				Note 2)
	Total assets	$3,924,625		$95,584	$	-		$	4,001,523			$	8,021,732
	At December 29, 2012	Core Standards,				Retail
		Contract Services and		Scientific and		Dietary Supplement
				Regulatory
		Ingredients segment		Consulting segment		Products segment		Other				Total
	Total assets	$3,542,355		$72,573		$4,331,866		$	1,087,727			$	9,034,521

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Jun. 30, 2012
Current Assets	'	'	'	'
Cash	$826,631	'	$520,000	$2,213,009
Trade receivables	1,186,529	'	1,940,539	'
Non-trade receivable	250,000	'	'	'
Inventories	1,944,597	'	5,205,304	'
Prepaid expenses and other assets	436,455	'	261,297	'
Total current assets	4,644,212	'	7,927,140	'
Leasehold Improvements and Equipment, net	1,012,963	'	936,426	'
Other Noncurrent Assets	'	'	'	'
Deposits	41,192	'	34,773	'
Long-term investment in affiliate	2,157,804	'	'	'
Intangible assets, net	165,561	'	136,182	'
Total other noncurrent assets	2,364,557	'	170,955	'
Total assets	8,021,732	'	9,034,521	'
Current Liabilities	'	'	'	'
Accounts payable	2,152,023	'	3,428,233	'
Accrued expenses	711,503	'	876,158	'
Current maturities of capital lease obligations	110,382	'	77,259	'
Customer deposits and other	336,824	'	310,267	'
Deferred rent, current	51,743	'	71,042	'
Total current liabilities	3,362,475	'	4,762,959	'
Capital lease obligations, less current maturities	238,287	'	148,374	'
Deferred rent, less current	152,456	'	129,859	'
Stockholders' Equity	'	'	'	'
Common stock	100,807	'	92,140	'
Additional paid-in capital	36,329,257	'	33,617,801	'
Accumulated deficit	-32,161,550	'	-29,716,612	'
Total stockholders' equity	4,268,514	3,841,677	3,993,329	'
Total liabilities and stockholders' equity	8,021,732	'	9,034,521	'
Scenario, Previously Reported [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash	826,631	'	'	'
Trade receivables	1,186,529	'	'	'
Non-trade receivable	250,000	'	'	'
Note receivable, current	1,623,508	'	'	'
Inventories	1,944,597	'	'	'
Prepaid expenses and other assets	436,455	'	'	'
Total current assets	6,267,720	'	'	'
Leasehold Improvements and Equipment, net	1,012,963	'	'	'
Other Noncurrent Assets	'	'	'	'
Deposits	41,192	'	'	'
Note receivable, less current	779,205	'	'	'
Long-term equity investment	2,678,832	'	'	'
Long-term investment in affiliate	'	'	'	'
Intangible assets, net	165,561	'	'	'
Total other noncurrent assets	3,664,790	'	'	'
Total assets	10,945,473	'	'	'
Current Liabilities	'	'	'	'
Accounts payable	2,152,023	'	'	'
Accrued expenses	711,503	'	'	'
Current maturities of capital lease obligations	110,382	'	'	'
Customer deposits and other	336,824	'	'	'
Deferred rent, current	51,743	'	'	'
Total current liabilities	3,362,475	'	'	'
Capital lease obligations, less current maturities	238,287	'	'	'
Deferred rent, less current	152,456	'	'	'
Stockholders' Equity	'	'	'	'
Common stock	100,807	'	'	'
Additional paid-in capital	36,329,257	'	'	'
Accumulated deficit	-29,237,809	'	'	'
Total stockholders' equity	7,192,255	'	'	'
Total liabilities and stockholders' equity	10,945,473	'	'	'
Restatement Adjustment [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash	'	'	'	'
Trade receivables	'	'	'	'
Non-trade receivable	'	'	'	'
Note receivable, current	-1,623,508	'	'	'
Inventories	'	'	'	'
Prepaid expenses and other assets	'	'	'	'
Total current assets	-1,623,508	'	'	'
Leasehold Improvements and Equipment, net	'	'	'	'
Other Noncurrent Assets	'	'	'	'
Deposits	'	'	'	'
Note receivable, less current	-779,205	'	'	'
Long-term equity investment	-2,678,832	'	'	'
Long-term investment in affiliate	2,157,804	'	'	'
Intangible assets, net	'	'	'	'
Total other noncurrent assets	-1,300,233	'	'	'
Total assets	-2,923,741	'	'	'
Current Liabilities	'	'	'	'
Accounts payable	'	'	'	'
Accrued expenses	'	'	'	'
Current maturities of capital lease obligations	'	'	'	'
Customer deposits and other	'	'	'	'
Deferred rent, current	'	'	'	'
Total current liabilities	'	'	'	'
Capital lease obligations, less current maturities	'	'	'	'
Deferred rent, less current	'	'	'	'
Stockholders' Equity	'	'	'	'
Common stock	'	'	'	'
Additional paid-in capital	'	'	'	'
Accumulated deficit	-2,923,741	'	'	'
Total stockholders' equity	-2,923,741	'	'	'
Total liabilities and stockholders' equity	-2,923,741	'	'	'
As Restated [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash	826,631	'	'	'
Trade receivables	1,186,529	'	'	'
Non-trade receivable	250,000	'	'	'
Note receivable, current	'	'	'	'
Inventories	1,944,597	'	'	'
Prepaid expenses and other assets	436,455	'	'	'
Total current assets	4,644,212	'	'	'
Leasehold Improvements and Equipment, net	1,012,963	'	'	'
Other Noncurrent Assets	'	'	'	'
Deposits	41,192	'	'	'
Note receivable, less current	'	'	'	'
Long-term equity investment	'	'	'	'
Long-term investment in affiliate	2,157,804	'	'	'
Intangible assets, net	165,561	'	'	'
Total other noncurrent assets	2,364,557	'	'	'
Total assets	8,021,732	'	'	'
Current Liabilities	'	'	'	'
Accounts payable	2,152,023	'	'	'
Accrued expenses	711,503	'	'	'
Current maturities of capital lease obligations	110,382	'	'	'
Customer deposits and other	336,824	'	'	'
Deferred rent, current	51,743	'	'	'
Total current liabilities	3,362,475	'	'	'
Capital lease obligations, less current maturities	238,287	'	'	'
Deferred rent, less current	152,456	'	'	'
Stockholders' Equity	'	'	'	'
Common stock	100,807	'	'	'
Additional paid-in capital	36,329,257	'	'	'
Accumulated deficit	-32,161,550	'	'	'
Total stockholders' equity	4,268,514	'	'	'
Total liabilities and stockholders' equity	$8,021,732	'	'	'

Restatement_of_Previously_Issu3

Restatement of Previously Issued Financial Statements (Details 1) (USD $)	3 Months Ended			6 Months Ended
	Jun. 29, 2013	Mar. 30, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Dec. 29, 2012
Sales	$2,706,896	'	$2,670,611	$5,041,462	$4,455,617	'
Cost of sales	1,746,158	'	1,905,916	3,407,884	4,295,136	'
Gross profit	960,738	'	764,695	1,633,578	160,481	'
Operating expenses:	'	'	'	'	'	'
Sales and marketing	631,559	'	1,868,418	1,360,983	3,727,080	'
General and administrative	1,342,280	'	2,883,728	2,702,181	4,845,639	'
Operating expenses	1,973,839	'	4,752,149	4,063,164	8,572,719	'
Operating income (loss)	-1,013,101	'	-3,987,451	-2,429,586	-8,412,238	'
Nonoperating income (expense):	'	'	'	'	'	'
Interest income	296	'	1,056	500	2,255	'
Interest expense	8,061	'	7,562	15,852	15,827	'
Nonoperating expenses	-7,765	'	-6,506	-15,352	-13,572	'
Net income (loss)	-1,020,866	-1,424,072	-3,993,957	-2,444,938	-8,425,810	'
Basic weighted average common shares outstanding	99,833,963	'	91,362,664	97,230,043	88,034,429	'
Cash Flows From Operating Activities	'	'	'	'	'	'
Net income (loss)	-1,020,866	-1,424,072	-3,993,957	-2,444,938	-8,425,810	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'	'	'	'
Depreciation of leasehold improvements and equipment	'	'	'	134,325	166,748	'
Amortization of intangibles	'	'	'	10,621	6,799	'
Share-based compensation expense	'	'	'	728,349	1,264,524	'
Gain on sale of assets	'	'	'	'	1,879	'
Changes in operating assets and liabilities:	'	'	'	'	'	'
Trade receivables	'	'	'	770,994	-264,536	'
Inventories	'	'	'	-206,824	-2,348,197	'
Prepaid expenses and other assets	'	'	'	-51,010	369,527	'
Accounts payable	'	'	'	-907,337	1,151,141	'
Accrued expenses	'	'	'	-150,095	-213,521	'
Customer deposits and other	'	'	'	26,557	-30,081	'
Deferred rent	'	'	'	3,298	-30,034	'
Net cash used in operating activities	'	'	'	-2,086,060	-8,351,561	'
Cash Flows From Investing Activities	'	'	'	'	'	'
Purchases of leasehold improvements and equipment	'	'	'	39,011	12,214	'
Purchase of intangible assets	'	'	'	40,000	2,000	'
Proceeds from sale of assets	'	'	'	750,000	'	'
Net cash provided by investing activities	'	'	'	670,989	-14,214	'
Cash Flows From Financing Activities	'	'	'	'	'	'
Proceeds from exercise of stock options	'	'	'	131,769	'	'
Proceeds from exercise of warrants	'	'	'	1,638,748	45,000	'
Principal payments on capital leases	'	'	'	48,815	44,806	'
Net cash provided by financing activities	'	'	'	1,721,702	10,158,632	'
Net increase in cash	'	'	'	306,631	1,792,857	'
Cash Ending of Period	826,631	'	2,213,009	826,631	2,213,009	520,000
Previously Reported [Member]	'	'	'	'	'	'
Sales	2,706,896	'	'	5,041,462	'	'
Cost of sales	1,746,158	'	'	3,407,884	'	'
Gross profit	960,738	'	'	1,633,578	'	'
Operating expenses:	'	'	'	'	'	'
Sales and marketing	631,559	'	'	1,360,983	'	'
General and administrative	1,342,280	'	'	2,702,181	'	'
Gain on sale of assets	'	'	'	-2,891,917	'	'
Operating expenses	1,973,839	'	'	1,171,247	'	'
Operating income (loss)	-1,013,101	'	'	462,331	'	'
Nonoperating income (expense):	'	'	'	'	'	'
Interest income	31,440	'	'	32,324	'	'
Interest expense	-8,061	'	'	-15,852	'	'
Nonoperating expenses	23,379	'	'	16,472	'	'
Net income (loss)	-989,722	'	'	478,803	'	'
Basic net income (loss) per common share	($0.01)	'	'	$0	'	'
Diluted net income (loss) per common share	($0.01)	'	'	$0	'	'
Basic weighted average common shares outstanding	99,833,963	'	'	97,230,043	'	'
Diluted weighted average common shares outstanding	99,833,963	'	'	97,486,066	'	'
Cash Flows From Operating Activities	'	'	'	'	'	'
Net income (loss)	-989,722	'	'	478,803	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'	'	'	'
Depreciation of leasehold improvements and equipment	'	'	'	134,325	'	'
Amortization of intangibles	'	'	'	10,621	'	'
Share-based compensation expense	'	'	'	728,349	'	'
Gain on sale of assets	'	'	'	-2,891,917	'	'
Interest added to note receivable	'	'	'	-31,824	'	'
Changes in operating assets and liabilities:	'	'	'	'	'	'
Trade receivables	'	'	'	770,994	'	'
Inventories	'	'	'	-206,824	'	'
Prepaid expenses and other assets	'	'	'	-51,010	'	'
Accounts payable	'	'	'	-907,337	'	'
Accrued expenses	'	'	'	-150,095	'	'
Customer deposits and other	'	'	'	26,557	'	'
Deferred rent	'	'	'	3,298	'	'
Net cash used in operating activities	'	'	'	-2,086,060	'	'
Cash Flows From Investing Activities	'	'	'	'	'	'
Purchases of leasehold improvements and equipment	'	'	'	-39,011	'	'
Purchase of intangible assets	'	'	'	-40,000	'	'
Proceeds from sale of assets	'	'	'	750,000	'	'
Net cash provided by investing activities	'	'	'	670,989	'	'
Cash Flows From Financing Activities	'	'	'	'	'	'
Proceeds from exercise of stock options	'	'	'	131,769	'	'
Proceeds from exercise of warrants	'	'	'	1,638,748	'	'
Principal payments on capital leases	'	'	'	-48,815	'	'
Net cash provided by financing activities	'	'	'	1,721,702	'	'
Net increase in cash	'	'	'	306,631	'	'
Cash Beginning of Period	'	'	'	520,000	'	'
Cash Ending of Period	826,631	'	'	826,631	'	'
Restatement Adjustment [Member]	'	'	'	'	'	'
Sales	'	'	'	'	'	'
Cost of sales	'	'	'	'	'	'
Gross profit	'	'	'	'	'	'
Operating expenses:	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'
General and administrative	'	'	'	'	'	'
Gain on sale of assets	'	'	'	2,891,917	'	'
Operating expenses	'	'	'	2,891,917	'	'
Operating income (loss)	'	'	'	-2,891,917	'	'
Nonoperating income (expense):	'	'	'	'	'	'
Interest income	-31,144	'	'	-31,824	'	'
Interest expense	'	'	'	'	'	'
Nonoperating expenses	-31,144	'	'	-31,824	'	'
Net income (loss)	-31,144	'	'	-2,923,741	'	'
Basic net income (loss) per common share	$0	'	'	($0.03)	'	'
Diluted net income (loss) per common share	$0	'	'	($0.03)	'	'
Basic weighted average common shares outstanding	'	'	'	'	'	'
Diluted weighted average common shares outstanding	'	'	'	-256,023	'	'
Cash Flows From Operating Activities	'	'	'	'	'	'
Net income (loss)	-31,144	'	'	-2,923,741	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'	'	'	'
Depreciation of leasehold improvements and equipment	'	'	'	'	'	'
Amortization of intangibles	'	'	'	'	'	'
Share-based compensation expense	'	'	'	'	'	'
Gain on sale of assets	'	'	'	2,891,917	'	'
Interest added to note receivable	'	'	'	31,824	'	'
Changes in operating assets and liabilities:	'	'	'	'	'	'
Trade receivables	'	'	'	'	'	'
Inventories	'	'	'	'	'	'
Prepaid expenses and other assets	'	'	'	'	'	'
Accounts payable	'	'	'	'	'	'
Accrued expenses	'	'	'	'	'	'
Customer deposits and other	'	'	'	'	'	'
Deferred rent	'	'	'	'	'	'
Net cash used in operating activities	'	'	'	'	'	'
Cash Flows From Investing Activities	'	'	'	'	'	'
Purchases of leasehold improvements and equipment	'	'	'	'	'	'
Purchase of intangible assets	'	'	'	'	'	'
Proceeds from sale of assets	'	'	'	'	'	'
Net cash provided by investing activities	'	'	'	'	'	'
Cash Flows From Financing Activities	'	'	'	'	'	'
Proceeds from exercise of stock options	'	'	'	'	'	'
Proceeds from exercise of warrants	'	'	'	'	'	'
Principal payments on capital leases	'	'	'	'	'	'
Net cash provided by financing activities	'	'	'	'	'	'
Net increase in cash	'	'	'	'	'	'
Cash Beginning of Period	'	'	'	'	'	'
Cash Ending of Period	'	'	'	'	'	'
As Restated [Member]	'	'	'	'	'	'
Sales	2,706,896	'	'	5,041,462	'	'
Cost of sales	1,746,158	'	'	3,407,884	'	'
Gross profit	960,738	'	'	1,633,578	'	'
Operating expenses:	'	'	'	'	'	'
Sales and marketing	631,559	'	'	1,360,983	'	'
General and administrative	1,342,280	'	'	2,702,181	'	'
Gain on sale of assets	'	'	'	'	'	'
Operating expenses	1,973,839	'	'	4,063,164	'	'
Operating income (loss)	-1,013,101	'	'	-2,429,586	'	'
Nonoperating income (expense):	'	'	'	'	'	'
Interest income	296	'	'	500	'	'
Interest expense	-8,061	'	'	-15,852	'	'
Nonoperating expenses	-7,765	'	'	-15,352	'	'
Net income (loss)	-1,020,866	'	'	-2,444,938	'	'
Basic net income (loss) per common share	($0.01)	'	'	($0.03)	'	'
Diluted net income (loss) per common share	($0.01)	'	'	($0.03)	'	'
Basic weighted average common shares outstanding	99,833,963	'	'	97,230,043	'	'
Diluted weighted average common shares outstanding	99,833,963	'	'	97,230,043	'	'
Cash Flows From Operating Activities	'	'	'	'	'	'
Net income (loss)	-1,020,866	'	'	-2,444,938	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'	'	'	'
Depreciation of leasehold improvements and equipment	'	'	'	134,325	'	'
Amortization of intangibles	'	'	'	10,621	'	'
Share-based compensation expense	'	'	'	728,349	'	'
Gain on sale of assets	'	'	'	'	'	'
Interest added to note receivable	'	'	'	'	'	'
Changes in operating assets and liabilities:	'	'	'	'	'	'
Trade receivables	'	'	'	770,994	'	'
Inventories	'	'	'	-206,824	'	'
Prepaid expenses and other assets	'	'	'	-51,010	'	'
Accounts payable	'	'	'	-907,337	'	'
Accrued expenses	'	'	'	-150,095	'	'
Customer deposits and other	'	'	'	26,557	'	'
Deferred rent	'	'	'	3,298	'	'
Net cash used in operating activities	'	'	'	-2,086,060	'	'
Cash Flows From Investing Activities	'	'	'	'	'	'
Purchases of leasehold improvements and equipment	'	'	'	-39,011	'	'
Purchase of intangible assets	'	'	'	-40,000	'	'
Proceeds from sale of assets	'	'	'	750,000	'	'
Net cash provided by investing activities	'	'	'	670,989	'	'
Cash Flows From Financing Activities	'	'	'	'	'	'
Proceeds from exercise of stock options	'	'	'	131,769	'	'
Proceeds from exercise of warrants	'	'	'	1,638,748	'	'
Principal payments on capital leases	'	'	'	-48,815	'	'
Net cash provided by financing activities	'	'	'	1,721,702	'	'
Net increase in cash	'	'	'	306,631	'	'
Cash Beginning of Period	'	'	'	520,000	'	'
Cash Ending of Period	$826,631	'	'	$826,631	'	'

Nature_of_Business_and_Signifi3

Nature of Business and Significant Accounting Policies (Details) (USD $)	Jun. 29, 2013	Dec. 29, 2012
Inventories	'	'
Natural product fine chemicals	$1,656,702	$1,614,755
Bulk ingredients	512,895	432,230
Dietary supplements - raw materials	'	401,809
Dietary supplements - work in process	'	465,253
Dietary supplements - finished goods	'	2,657,257
Inventory-gross	2,169,597	5,571,304
Less valuation allowance	225,000	366,000
Inventory-net	$1,944,597	$5,205,304

Nature_of_Business_and_Signifi4

Nature of Business and Significant Accounting Policies (Details 1)	3 Months Ended		6 Months Ended
	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012
Earnings per share	'	'	'	'
Basic weighted average common shares outstanding	99,833,963	91,362,664	97,230,043	88,034,429
Warrants and options in the money, net	319,587	5,693,386	256,023	6,101,236
Weighted average common shares outstanding assuming dilution	100,153,550	97,056,050	97,486,066	94,135,665

Nature_of_Business_and_Signifi5

Nature of Business and Significant Accounting Policies (Details Narrative) (USD $)	Jun. 29, 2013	Dec. 29, 2012	Jun. 30, 2012
Nature Of Business And Significant Accounting Policies Details Narrative	'	'	'
Inventory valuation allowances	$225,000	$366,000	'
Not in the money warrants and options	11,595,211	'	15,071,066
Hold on receivable amount	'	433,000	'
Allowance for doubtful accounts	$17,000	$450,000	'

Sale_of_Product_Line_and_Inves2

Sale of Product Line and Investment in Affiliate (Details) (USD $)	Mar. 28, 2013
Assets transferred	'
Trade receivables, less allowance for returns	($16,984)
Inventories	3,467,530
Prepaid expenses and other assets	76,131
Total assets transferred	3,526,677
Liabilities transferred	'
Accounts payable	368,873
Total liabilities transferred	368,873
Total net assets transferred	3,157,804
Initial monetary consideration received	'
Cash	500,000
Non-trade receivable	500,000
Total initial monetary consideration received	1,000,000
Carrying Value of Long Term Investment in Affiliate	$2,157,804

Sale_of_Product_Line_and_Inves3

Sale of Product Line and Investment in Affiliate (Details Narrative) (USD $)	6 Months Ended
	Jun. 29, 2013	Mar. 28, 2013
Second payment toward additional payment amount	$200,000	'
Carrying value, equity investment, beginning balance	'	2,157,804
NeutriSci [Member]	'	'
Sale transaction value	3,157,804	'
Deposit	250,000	'
Closing payment	250,000	'
Additional payment amount	500,000	'
Payment toward additional payment amount	250,000	'
Second payment toward additional payment amount	200,000	'
Unpaid cash payment due at June 29, 2013	250,000	'
Convertible shares	625,000	'
Quarterly installment	416,667	'
Series I preferres shares issued	669,708	'
Series I conversion into Class A Common Shares	2,678,832	'
Class A common percent of deemed shares	19.00%	'
Class A price per share	$1	'
Royalty due to company on future net sales, rate	6.00%	'
Carrying value, equity investment, beginning balance	$2,157,804	'
Series I Conversion rate per share	$4	'

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Jun. 29, 2013	Dec. 29, 2012
Leasehold Improvements And Equipment Details	'	'
Laboratory equipment	$2,563,238	$2,439,688
Leasehold improvements	403,971	403,971
Computer equipment	370,692	363,739
Furniture and fixtures	18,313	18,313
Office equipment	7,877	7,877
Construction in progress	186,439	106,080
Leasehold Improvements and Equipment-gross	3,550,530	3,339,668
Less accumulated depreciation	2,537,567	2,403,242
Leasehold Improvements and Equipment-net	$1,012,963	$936,426

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (Options [Member])	6 Months Ended
	Jun. 29, 2013
Options [Member]	'
Volatility	32.68%
Expected dividends	0.00%
Expected term	'6 years 1 month 6 days
Risk-free rate	1.18%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (ServicePeriodBasedStockOptions [Member], USD $)	6 Months Ended
	Jun. 29, 2013
ServicePeriodBasedStockOptions [Member]	'
Number of Shares	'
Outstanding at December 29, 2012	12,202,558
Options Granted	310,000
Options Exercised	-13,538
Options Expired	-75,000
Options Forfeited	-149,168
Outstanding at June 29, 2013	12,274,852
Exercisable at June 29, 2013	6,035,944
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.08
Options Granted	$0.68
Options Exercised	$0.50
Options Expired	$0.50
Options Forfeited	$1.24
Outstanding at June 29, 2013	$1.08
Exercisable at June 29, 2013	$1.24
Weighted Average Remaining Contractual Term	'
Outstanding at June 29, 2013	'7 years 10 months 10 days
Exercisable at June 29, 2013	'6 years 5 months 23 days
Aggregate Intrinsic Value	'
Outstanding at June 29, 2013	$375,554
Exercisable at June 29, 2013	$202,092

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (Performance Based Stock Options [Member], USD $)	6 Months Ended
	Jun. 29, 2013
Performance Based Stock Options [Member]	'
Summary of performance based stock option activity- Shares	'
Outstanding at December 29, 2012	145,834
Options Granted	200,000
Options Exercised	'
Options Expired	'
Options Forfeited	-45,834
Outstanding at June 29, 2013	300,000
Exercisable at June 29, 2013	52,084
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.59
Options Granted	$0.63
Options Exercised	'
Options Expired	'
Options Forfeited	$1.59
Outstanding at June 29, 2013	$0.95
Exercisable at June 29, 2013	$1.59
Weighted Average Remaining Contractual Term	'
Outstanding at June 29, 2013	'9 years
Exercisable at June 29, 2013	'7 years 10 months 6 days
Aggregate Intrinsic Value	'
Outstanding at June 29, 2013	$30,200
Exercisable at June 29, 2013	'

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (Restricted Stock [Member], USD $)	6 Months Ended
	Jun. 29, 2013
Restricted Stock [Member]	'
Summary of activity of restricted stock awards granted to employees- Shares	'
Unvested shares at December 29, 2012	500,000
Granted	'
Vested	'
Forfeited	'
Unvested shares at June 29, 2013	500,000
Expected to Vest as of June 29, 2013	500,000
Weighted Average Award-Date Fair Value	'
Unvested shares at December 29, 2012	$0.69
Granted	'
Vested	'
Forfeited	'
Unvested shares at June 29, 2013	$0.69
Expected to Vest as of June 29, 2013	$0.69

Employee_Share_Based_Compensat

Employee Share Based Compensation (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012
General and Administrative Expense [Member]	'	'	'	'
Recognized share based compensation expense (income)	$286,417	$939,960	$572,951	$643,825
Options [Member]	'	'	'	'
Expiration dates for stock options not exceeds	'	'	'10 years	'
Authorized stock options	'	'	20.00%	'
Remaining amount available for issuance	'	'	6,164,537	'
Unrecognized compensation expense	1,945,157	'	1,945,157	'
Cost is expected to be recognized over a weighted average period	'P2Y5M8D	'	'P2Y5M8D	'
Realized tax benefit from stock options	'	'	0	'
ServicePeriodBasedStockOptions [Member]	'	'	'	'
Closing stock price	$0.78	'	$0.78	'
Aggregate intrinsic value of options exercised	'	'	2,437	'
Weighted average fair value of options granted	'	'	$0.24	$0.30
Performance Based Stock Options [Member]	'	'	'	'
Closing stock price	$0.78	'	$0.78	'
Weighted average fair value of options granted	'	'	$0.22	'
Restricted Stock [Member]	'	'	'	'
Unrecognized compensation expense	$0	'	$0	'

NonEmployee_ShareBased_Compens2

Non-Employee Share-Based Compensation (Details) (USD $)	6 Months Ended
	Jun. 29, 2013
Non-Employee Share-Based Compensation- Options	'
Outstanding at December 29, 2012	1,097,300
Options Granted	'
Options Exercised	-250,000
Options Forfeited	'
Outstanding at June 29, 2013	847,300
Exercisable at June 29, 2013	847,300
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.23
Options Granted	'
Options Exercised	$0.50
Options Forfeited	'
Outstanding at June 29, 2013	$1.44
Exercisable at June 29, 2013	$1.44
Weighted Average Remaining Contractual Term	'
Outstanding at June 29, 2013	'6 years 2 months 23 days
Exercisable at June 29, 2013	'6 years 2 months 23 days
Aggregate Intrinsic Value	'
Outstanding at June 29, 2013	$11,670
Exercisable at June 29, 2013	$11,670

NonEmployee_ShareBased_Compens3

Non-Employee Share-Based Compensation (Details Textuals) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 29, 2013

Jun. 29, 2013

Jun. 29, 2013

Jun. 30, 2012

Jun. 29, 2013

Jun. 30, 2012

Jun. 29, 2013

Jun. 29, 2013

Jun. 29, 2013

Jun. 30, 2012

Jun. 29, 2013

Jun. 30, 2012

NonEmployee Share Based Compensation [Member]

NonEmployee Share Based Compensation [Member]

NonEmployee Share Based Compensation [Member]

NonEmployee Share Based Compensation [Member]

NonEmployee Share Based Compensation [Member]

NonEmployee Share Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

NonEmployee Shared Based Compensation [Member]

Stock Options [Member]

Stock Options [Member]

StockAward [Member]

StockAward [Member]

StockAward [Member]

StockAward [Member]

WarrantAward [Member]

WarrantAward [Member]

GeneralAndAdministrativeExpenses [Member]

GeneralAndAdministrativeExpenses [Member]

GeneralAndAdministrativeExpenses [Member]

GeneralAndAdministrativeExpenses [Member]

Closing stock price

$0.78

$0.78

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value nonemployee options exercised

$35,000

$35,000

'

'

'

'

'

'

'

'

'

'

Shares awarded during the period

'

'

160,000

265,000

600,000

454,557

'

'

'

'

'

'

Share-based compensation expense

'

'

88,071

181,260

150,249

308,176

1,334

4,094

90,342

258,578

155,398

620,700

Unrecognized compensation expense

'

'

'

'

$230,276

'

'

'

'

'

'

'

Warrants_Details

Warrants (Details) (USD $)	Jun. 29, 2013
PrivatePlacementEquityOffering2008Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$3
Number Outstanding And Exercisable At June 29, 2013	404,047
Weighted Average Remaining Contractual Life	'24 days
PlacementAgentCommission2012Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.85
Number Outstanding And Exercisable At June 29, 2013	285,000
Weighted Average Remaining Contractual Life	'1 year 1 month 3 days
NonEmployeeAward2010Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.75
Number Outstanding And Exercisable At June 29, 2013	250,000
Weighted Average Remaining Contractual Life	'1 year 1 month 9 days
TotalMember	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$1.75
Number Outstanding And Exercisable At June 29, 2013	939,047
Weighted Average Remaining Contractual Life	'7 months 27 days

Warrants_Details_Narrative

Warrants (Details Narrative) (USD $)	3 Months Ended	6 Months Ended
	Jun. 29, 2013	Jun. 29, 2013
Warrants Details Narrative	'	'
Proceeds from exercise of warrants	$921,749	$1,638,748
exercise of warrants, shares	4,389,281	7,803,564
Exercise price of warrant	$0.21	$0.21
Warrants expired	533,067	1,314,303
Exercise price of warrants expired	$3	$3

Business_Segmentation_Details

Business Segmentation (Details) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012
					CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	Other Segment [Member]	Other Segment [Member]	Other Segment [Member]	Other Segment [Member]
Net sales	$2,706,896	$2,670,611	$5,041,462	$4,455,617	$2,504,372	$2,150,585	$4,655,885	$4,005,333	$202,524	'	$445,862	'	'	$520,026	($60,285)	$450,284	'	'	'	'
Cost of sales	1,746,158	1,905,916	3,407,884	4,295,136	1,614,413	1,528,203	3,128,396	2,874,825	131,745	'	278,533	'	'	377,713	955	1,420,311	'	'	'	'
Gross profit	960,738	764,695	1,633,578	160,481	889,959	622,382	1,527,489	1,130,508	70,779	'	167,329	'	'	142,313	-61,240	-970,027	'	'	'	'
Sales and marketing	631,559	1,868,418	1,360,983	3,727,080	630,447	536,572	1,227,224	1,011,516	1,112	'	2,600	'	'	1,331,846	131,159	2,715,564	'	'	'	'
General and Administrative	1,342,280	2,883,728	2,702,181	4,845,639	'	'	'	'	'	'	'	'	'	'	'	'	1,342,280	2,883,728	2,702,181	4,845,639
Operating expenses	1,973,839	4,752,149	4,063,164	8,572,719	630,447	536,572	1,227,224	1,011,516	1,112	'	2,600	'	'	1,331,846	131,159	2,715,564	1,342,280	2,883,728	2,702,181	4,845,639
Operating income (loss)	($1,013,101)	($3,987,451)	($2,429,586)	($8,412,238)	$259,512	$85,810	$300,265	$118,992	$69,667	'	$164,729	'	'	($1,189,533)	($192,399)	($3,685,591)	($1,342,280)	($2,883,728)	($2,702,181)	($4,845,639)

Business_Segmentation_Details2

Business Segmentation (Details2) (USD $)	Jun. 29, 2013	Dec. 29, 2012
Total assets	$8,021,732	$9,034,521
CoreStandardsContractServices [Member]	'	'
Total assets	3,924,625	3,542,355
ScientificRegulatory [Member]	'	'
Total assets	95,584	72,573
RetailDietarySupp [Member]	'	'
Total assets	'	4,331,866
Other Segment [Member]	'	'
Total assets	$4,001,523	$1,087,727

Managements_Plans_for_Continui1

Management's Plans for Continuing Operations (Details Textuals) (USD $)	3 Months Ended			6 Months Ended
	Jun. 29, 2013	Mar. 30, 2013	Jun. 30, 2012	Jun. 29, 2013	Jun. 30, 2012
Management's Plans for Continuing Operations	'	'	'	'	'
Net loss	($1,020,866)	($1,424,072)	($3,993,957)	($2,444,938)	($8,425,810)
Operating loss	-1,013,101	'	-3,987,451	-2,429,586	-8,412,238
Share based compensation expense	'	'	'	728,349	'
Operating loss from BluScience	'	'	'	192,399	'
Second payment toward additional payment amount	'	'	'	200,000	'
Additional amount expected to receive 2013 from sale of BluScience	'	'	'	$883,334	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	1 Months Ended
	Aug. 08, 2013
Subsequent Events [Abstract]	'
Minimum purchase commitment	$3,500,000